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In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall
survival (OS) (HR 1.8; 95% CI: 1.3–2.5, P¼0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9
above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS (HR 1.9;
95% CI: 1.1–3.4, P¼0.019).
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Over the last decade, systemic chemotherapy has become a
standard therapy for patients with inoperable pancreatic cancer.
Prior to this, the lack of randomised data and the perceived
toxicity of treatment led most clinicians to believe that cytotoxic
therapy would not be of palliative benefit or could significantly
prolong their patients’ lives. Following a number of randomised
clinical trials, it became clear that not only did chemotherapy offer
a small but significant survival benefit, but there was also evidence
supporting an improvement in quality of life. Over the last decade,
a number of relatively large and well-conducted phase III trials
have attempted to define the optimal chemotherapy schedule for
this cohort of patients. Currently, the standard of care is
gemcitabine, following the seminal paper by Burris et al (1997).
A number of ongoing trials are exploring the potential benefit of
gemcitabine scheduling, combination with other chemotherapeutic
agents and the addition of novel agents such as antibodies to the
epidermal growth factor receptor and vascular endothelial growth
factor.
In the mid 1990s, the CONSORT (Consolidated Standards of
Reporting Trials) statement was published, which was intended to
improve the quality of reporting of phase III trials (Moher et al,
2001). The CONSORT statement consists of a checklist and a
diagram intended for use in writing, reviewing or assessing reports
of randomised controlled trials. One of the items in the checklist is
the reporting of baseline demographic and clinical characteristics
of each group.
When assessing the results of a phase III trial, it is clearly vital
that the known important prognostic factors are balanced between
treatment arms to allow a fair comparison of treatment effect.
Despite a small number of publications suggesting that the tumour
marker CA19-9 is an important prognostic variable (Gogas et al,
1998; Halm et al, 2000; Saad et al, 2002; Stemmler et al, 2003; Ziske
et al, 2003), none of the large published randomised studies of
chemotherapy to date have reported baseline CA19-9 levels.
The aim of this retrospective analysis was to investigate whether
CA19-9 provided prognostic information in patients with inoper-
able pancreatic cancer treated with systemic chemotherapy, and
should therefore be reported in future randomised controlled
trials.
MATERIALS AND METHODS
All patients treated with gemcitabine- and/or 5-fluorouracil-based
chemotherapy in three consecutive phase III randomised trials at
this centre were eligible for analysis. Patients had inoperable or
metastatic histologically proven pancreatic cancer, were of WHO
performance status (PS) 0–2 and had radiologically measurable
disease. All patients were previously untreated. Entry criteria
included a total serum bilirubin level of 30mmoll
 1 or less.
Informed written consent was obtained from all patients.
Treatment
All eligible patients received one of four chemotherapy regimens.
Protracted venous infused 5-fluorouracil (PVI 5FU) was either
given alone (at a dose of 300mgm
 2day
 1 for a maximum of 24
weeks) or in combination with mitomycin C (MMC) administered
at a dose of 7mgm
 2 6 weekly for four courses. The remainder
received a combination of gemcitabine (1000mgm
 2 on days 1, 8
and 15 of a 28-day cycle) and capecitabine (830mgm
 2 twice daily
for 21 days followed by a week’s break) or gemcitabine alone, at a
dose of 1000mgm
 2 weekly for 7 weeks, followed by a week’s
break and subsequently for 3 weeks out of every 4.
Measurements
Serum CA19-9 was measured at baseline (defined as being within
30 days before the start of chemotherapy) and subsequently every
6 weeks while the patients remained on treatment. The CA19-9
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sconcentration was measured by an automated, commercially
available enzyme immunoassay on an axsym analyser (Abbott
Diagnostics Laboratory). A value of 37Uml
 1 was used as the
upper limit of normal.
Statistics
All data were recorded prospectively on the Gl unit database.
Overall survival (OS) (defined as time from randomisation to
death from any cause) was examined with the Kaplan–Meier
product limit method (Kaplan and Meier, 1958), and survival in
patients with baseline CA19-9 values that fell above or below the
median level (median dichotomised) was compared with the log-
rank test (Peto and Peto, 1972). Statistical analysis was performed
using the statistical package SPSS for Windows version 12.01.
Multivariate logistic regression was used to determine factors
predictive of survival. Factors included in these analyses were
baseline CA19-9, a 20% drop in CA19-9 level following the start
of chemotherapy, age, sex, the presence of locally advanced or
metastatic disease and performance status. A fall of 20% in the
CA19-9 level was chosen after review of similar analyses in the
literature. P-values of less than 0.05 were considered statistically
significant.
RESULTS
Patients
Between July 1994 and July 2004, 218 patients received chemo-
therapy in the context of a clinical trial. Of these patients, 154
had a CA19-9 level recorded within 30 days before the start of
chemotherapy at this centre. Baseline demographics are given in
Table 1.
CA19-9 levels
Baseline CA19-9 levels were recorded in 154 patients. The median
time of performing the test was 1 day prior to the start of
chemotherapy (range 0–30). The median baseline CA19-9 level
was 958Uml
 1.
Post-treatment CA19-9 was recorded in 88 patients. The median
time of performing the test from the start of chemotherapy was 42
days, ranging from 28 to 55 days. The median post-treatment
CA19-9 level was 998Uml
 1. There was no significant difference
in the time to progression (TTP) between the cohort that had
CA19-9 levels performed at baseline and following chemotherapy,
compared with the cohort that had baseline levels only (P¼0.46).
Survival
The median follow-up in those patients with a recorded baseline
CA19-9 level was 712 days and 92% had died at the time of
analysis. The median OS in patients with a baseline CA19-9 below
the median value was significantly superior to those with a value
above (337 vs 165 days, P¼0.0004). The 1-year OS was 19 and
46%, respectively, for patients with a baseline CA19-9 above or
below the median value (see Figure 1).
In a multivariate analysis, baseline CA19-9 above or below the
median value (958Uml
 1) was found to be an independent
prognostic factor for OS (HR 1.8; 95% CI: 1.3–2.5, P¼0.0004).
A fall of 20% in CA19-9 level at first measurement following the
start of treatment was an independent prognostic factor for OS
(HR 1.9; 95% CI: 1.1–3.4, P¼0.019). Baseline characteristics in
this group were not significantly different from the original cohort.
Other factors that were found to be independent prognostic
factors for OS were sex and performance status (PS) (see Table 2).
DISCUSSION
Ensuring an equal balance of prognostic factors between treatment
arms in randomised controlled trials is vital. This may be
particularly relevant when the clinical benefit of an intervention
is likely to be small, as is the case for patients with advanced
pancreatic cancer. A number of both patient- and disease-related
factors have been identified as independent prognostic markers,
including PS, sex and the presence of metastases, and are routinely
quoted in clinical studies as baseline characteristics. There have
also been several reports of various biological markers that may
carry some prognostic significance. These include growth factors
such as vascular endothelial growth factor and platelet-derived
endothelial cell growth factor (Fujimoto et al, 1998), microsatellite
instability (Nakata et al, 2002), tumour suppression gene
expression such as SMAD4 (Biankin et al, 2002) and the expression
of mutated genes controlling response to DNA damage, such as
GADD45a and p53 (Yamasawa et al, 2002).
The serum carbohydrate antigen CA19-9 is a tumour-associated
antigen that has been shown to be a highly specific and sensitive
serum marker for pancreatic cancer (Pleskow et al, 1989;
Rollhauser and Steinberg, 1998). CA19-9 is a sialylated Lewis
blood group antigen targeted by the monoclonal antibody 1116 NS
19-9 (Koprowski et al, 1979). Previous studies have demonstrated
a prognostic role for pretreatment CA19-9 in patients receiving
radiotherapy (Katz et al, 1998) or undergoing pancreatic resection
(Glenn et al, 1988). Although a small number of papers have
described a fall in CA19-9 to be an independent prognostic
variable for survival (Gogas et al, 1998; Saad et al, 2002; Stemmler
et al, 2003; Ziske et al, 2003), there have been surprisingly few
studies investigating the use of baseline CA19-9 in predicting
survival for patients with inoperable pancreatic cancer who
undergo systemic chemotherapy. Halm et al (2000) reported the
survival of 43 consecutive patients with advanced pancreatic
cancer treated with single-agent gemcitabine. In a multivariate
Table 1 Baseline patient characteristics
Characteristic
Total patient
cohort
Patients with
baseline CA19-9
Patients with
pre- and post-
treatment
CA19-9
n 218 154 88
Median age (range)
(years)
63 (28–86) 63 (28–86) 63 (42–86)
Male (%) 62.8 63.6 62.5
Disease extent (%)
Metastatic 62.8 66.2 64.7
Locally advanced 37.2 33.8 35.3
Performance status (%)
0 12.8 12.9 17.0
1 56.9 62.3 62.5
2 25.7 24.7 20.5
3 0.9 — —
Not documented 3.7 — —
Chemotherapy received (%)
None 4 0 0
PVI 5FU 48 51 45.5
PVI 5FU+MMC 33 28 21.6
GEM 6 8.5 19.4
GEM+CAP 9 12.5 12.5
Other 0 0 1
PVI 5FU¼protracted venous infused 5-fluorouracil, MMC¼mitomycin C, GEM¼
gemcitabine, CAP¼capecitabine.
CA19-9 in pancreatic cancer
NR Maisey et al
741
British Journal of Cancer (2005) 93(7), 740–743 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
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prognostic predictor of survival with a relative risk of death 1.4
(95% CI: 1.0–2.0, P¼0.04). Ziske et al (2003) published their
results in a similar cohort of patients (n¼46). Although they did
not report baseline CA19-9 level as a prognostic variable, they did
find that a fall of at least 20% in CA19-9 level following the start
of chemotherapy was the only independent prognostic marker for
OS in their Cox multivariate analysis. An important caveat in the
interpretation of CA19-9 levels in pancreatic cancer is the presence
of biliary obstruction, which results in the elevation of the marker
level. In the current series, however, entry criteria mandated that
serum bilirubin should be 30mmoll
 1 or less, and therefore this
potential pitfall was avoided in the interpretation of baseline
CA19-9 levels.
The results of this study suggest that baseline tumour marker
CA19-9 is an important independent prognostic variable in
patients with inoperable pancreatic cancer. We found that baseline
CA19-9 above or below the median value (958Uml
 1) was an
independent prognostic factor for OS (HR 1.8; 95% CI: 1.3–2.5,
P¼0.0004), with a 1-year OS of 19 and 46%, respectively. Although
this is the largest reported series examining the predictive value of
baseline CA19-9 in patients treated with systemic chemotherapy,
it is still a relatively small cohort of 154 patients, and further
studies would be welcome to consolidate these results. However,
considering its apparent prognostic value, future randomised
controlled trials should consider reporting median CA19-9 levels
in treatment groups as part of routine demographic data.
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Figure 1 Overall survival and pre-treatment CA19-9 level.
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